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1. Introduction 
The hallmark of cancer cells is deregulated growth, inhibition of differentiation, and delay 
or blockage of programmed cell death. Tumor cells that are independent of extra- and/or 
intracellular regulatory mechanisms due to mutations in proto-oncogenes and tumor 
suppressors acquire the ability of uncontrolled proliferation and invasion into other tissues.  
FOXO (FOXO1, FOXO3, FOXO4, FOXO6) transcription factors control apoptosis, stress 
resistance and longevity in mammalian cells. Their activity and subcellular localization is 
regulated by phosphorylation on conserved serine/threonin residues via protein kinase B 
(PKB) and stress-induced kinases. Hyperactivation of PKB contributes to the inactivation of 
FOXO3 and predicts poor outcome for neuroblastoma patients. Depending on their post-
translational modifications and cellular context FOXO transcription factors exert diverse 
functions thereby either inducing cell death but also cell survival and resistance to 
environmental stress. Although FOXO transcription factors share the same DNA binding 
motive and seem to have overlapping functions, knock out animals for single FOXO family 
members show different defects: Whereas FOXO1 knock-out mice die during embryonic 
development due to defective vasculature, FOXO3 and FOXO4 knock out mice show a mild 
phenotype. However, conditional triple-knock-out mice provide evidence that FOXO1, 
FOXO3 and FOXO4 are critically involved in the maintenance of the hematopoietic stem cell 
population and the regulation of endothelial cell homeostasis. Consistent with their putative 
role as tumor suppressors, in cultured neuroblastoma cells the activation of FOXO3 triggers 
the intrinsic death pathway and induces programmed cell death via induction of the pro-
apoptotic BH3-only proteins BCL2L11/Bim and PMAIP1/Noxa. Surprisingly, in 
neuroblastoma cells FOXO3-mediated cell death depends on the accumulation of reactive 
oxygen species (ROS). Activation of FOXO3 also causes the repression of the apoptosis-
inhibitor protein Survivin and determines sensitivity of neuroblastoma cells to DNA-
damaging chemotherapeutic agents. More recently it was shown that beside its function as a 
tumor suppressor FOXO3 might also facilitate cancer cell survival under certain 
circumstances. In other tumor types FOXO3 also induces detoxification and stress resistance 
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thereby contributing to tumor stem cell renewal and protection of cancer cells from 
eradication during chemotherapy. In this respect FOXO3 was recently shown to be essential 
for the maintenance of leukemia initiating cells in chronic myeloid leukemia and to confer 
therapy resistance in leukemia cells. Active FOXO3 facilitates metastasis through activation 
of matrix metalloproteinases, leads to lymph node positivity and predicts poor survival in 
breast carcinoma. In this article we will therefore review the current knowledge of FOXO 
transcription factors, their “Janus-faced role” in tumor cell survival and drug sensitivity and 
discuss whether FOXO3 might be an interesting target for therapeutic intervention in 
neuroblastoma. 
2. A general overview on FOXOs 
The forkhead transcription factor family consists of more than 100 members, which are 
important in various processes including development, cellular differentiation, proliferation, 
cell cycle arrest, cell death, tumor suppression, stress resistance and metabolism (Carlsson 
and Mahlapuu 2002). In mammals four members of the forkhead transcription factor class O 
(FOXO) family are known, named FKHR/FOXO1, FKHRL1/FOXO3, AFX/FOXO4 and 
FOXO6 (Katoh and Katoh 2004). FOXO transcription factors are homologs of the 
Caenorhabditis elegans protein DAF-16 which regulates the life-span of C. elegans (Lin et al, 
1997) and were first discovered through the cloning of chromosomal breakpoints associated 
with cancer. Since the chromosomal translocation disrupted the FOXO-DNA-binding 
domain in the oncogenic fusion protein it was proposed that all three FOXOs act as tumor 
suppressors. FOXO proteins function primarily as transcription factors in the nucleus and 
bind as monomers to a consensus DNA sequence with a DNA-binding “winged-helix” 
domain, also called forkhead box, a 110 amino acid region in the central part of the protein 
(Weigelt et al, 2001). FOXO factors bind to the DNA-binding motif TTGTTTAC, 
TT(G/A)TTTTC and (C/A)(A/C)AAA(C/T)AA (Obsil and Obsilova 2010; Furuyama et al, 
2000). Bioinformatics analyses showed that a large set of genes contain FOXO-binding sites 
in their promoter region (Xuan and Zhang 2005). FOXO proteins act as potent 
transcriptional activators, but gene array analyses indicate that FOXOs can also act as 
transcriptional repressors (Ramaswamy et al, 2002).  
To specify the diverse functions of FOXO transcription factors, knock-out mice were 
generated. These approaches revealed distinct but overlapping roles of FOXO members in 
mammals. FOXO1 null mice die during embryonic development due to defective 
vascularization (Hosaka et al, 2004). In vitro experiments further suggest that FOXO1 is 
important for endothelial cells to respond to vascular endothelial growth factor (VEGF). 
FOXO3 null mice are viable but exhibit an age-dependent female infertility as a consequence 
of abnormal follicular activation leading to total depletion of ovarian follicles (reviewed in 
(Arden 2008a)). Furthermore FOXO3 null mice show defects in the glucose uptake 
(Castrillon et al, 2003). This implies a role of FOXO factors in glucose metabolism. In 
lymphoid organs, FOXO3 is the predominant FOXO member and its deficiency leads to 
lymphoproliferation and widespread organ inflammation. FOXO4 null mice are viable and 
show no overt phenotype (Hosaka et al, 2004). Since all three FOXO transcription factors 
recognize the same DNA consensus sequence, the three family members seem to have 
overlapping functions. Since there is possible functional redundancy between the family 
members, a triple knock-out mouse with conditional deletions of FOXO1, FOXO3 and 
FOXO4 was developed. These animals show abnormalities in lymphoid development and a 
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defect in the long-term repopulating activity of the bone-marrow stem cells. Additionally, 
these mice have a significant reduction in their long-term hematopoietic stem cell 
population and a decrease in a subset of genes, which are involved in detoxification and 
prevention of oxidative stress (Tothova et al, 2007b). This suggests that FOXOs play a major 
role in the response to oxidative stress (Arden 2008b). Furthermore the inactivation of all 
three FOXO transcription factors results in lymphoblastic thymic lymphomas, leukemias 
and widespread hemangiomas (Paik et al, 2007). Since these animal models support a 
critical role of FOXOs in the homeostasis of the stem cell population, deregulation of FOXOs 
might contribute to the development of various malignancies, among them human 
neuroblastoma. 
3. Regulation of FOXOs by survival and stress signaling 
FOXO proteins are post-translationally regulated by phosphorylation, acetylation or 
ubiquitination via different signaling pathways. These modifications determine the cellular 
localization of FOXO proteins and the interaction with binding partners. In the absence of 
growth factors, FOXO3 localizes to the nucleus. Binding of growth factors such as insulin, 
insulin-like-growth factor (IGF) or neurotrophic factors (nerve growth factor (NGF), brain-
derived-neurotrophic-factor (BDNF), neurotrophin-3, -4 (NT-3, -4)) to their cognate 
receptors induce a signaling cascade that leads to the activation of phosphatidylinositol-3-
kinase (PI3K) and the production of phosphoinositol-3-phosphate (PIP3). The second 
messenger PIP3 serves as an adapter molecule for pleckstrin homology (PH)-domain 
containing proteins at the cytoplasma membrane, such as the protein kinase B (PKB). The 
molecular interaction of these proteins at the membrane induces their 
(auto)phosphorylation and activation (reviewed in (Coffer and Burgering 2004)). When 
activated, PKB phosphorylates FOXO transcription factors on three highly conserved sites 
(e.g. FOXO3 on threonin-32, serine-253, serine-315), one located in the forkhead domain, one 
at the N-terminal and one at the C-terminal site. Phosphorylation by PKB masks the nuclear 
localization sequence (NLS) of FOXO3 and impedes DNA-binding. Furthermore PKB 
phosphorylation prevents the interaction with the transcriptional co-activator p300/CBP 
and promotes binding of FOXO proteins to 14-3-3. Following this binding FOXO3 
undergoes a conformational change that results in the exposure of a nuclear export sequence 
(NES) on its C-terminal site and causes the export of FOXO3 into the cytoplasm (Biggs et al, 
1999; Brunet et al, 1999). This conformational change allows FOXO3 to interact with 
Exportin/Crm1 and Ran, which leads to its export into the cytoplasm via the nuclear pore 
complex, repression of its transcriptional activity and to ubiquitin-mediated proteasomal 
degradation. Nuclear re-import is prevented due to masking of its NLS by 14-3-3 proteins 
(Rena et al, 2002). The PI3K-PKB signaling pathway is negatively regulated by phosphatases 
such as PTEN (Yamada and Araki 2001) that degrade PIP3 and thereby abrogate this 
signaling cascade. Loss of PTEN is frequently observed in carcinomas (Li et al, 1997) and 
hematologic malignancies (Sakai et al, 1998). The overexpression of growth factors that 
activate the PI3K or mutations in its regulatory subunits also result in hyperactivation of the 
PI3K-PKB pathway. PKB is dysregulated in a variety of cancers such as neuroblastoma 
(Opel et al, 2007). In addition to PKB, also the serum and glucocorticoid-inducible kinase 
(SGK) and the cyclin-dependent-kinase-2 (CDK2) phosphorylate FOXOs at distinct sites, 
which triggers their export from the nucleus (reviewed in (Coffer and Burgering 2004)). 
Other kinases which phosphorylate FOXO3 are the serine/threonine kinase CK1 (Rena et al, 
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2002) and the dual tyrosine phosphorylated regulated kinase 1 (DYRK1), which belongs to 
the MAP kinase family (Woods et al, 2001). 
 
 
Growth factors such as IGF-1 lead to activation of PKB and CDK2 via PI3K-dependent pathways resulting 
in phosphorylation of FOXOs at distinct sites. A) PKB-mediated phosphorylation induces the binding of 
the chaperone protein 14-3-3 and subsequent export into the cytoplasm. B) CDK2-mediated 
phosphorylation also leads to cytoplasmic localization. Upon DNA-damage the CDK2-triggered 
phosphorylation activates FOXOs. C) Skp2 of the SCF-E3 ligase complex interacts with and ubiquitylates 
FOXO1. D) In response to oxidative stress FOXOs translocate into the nucleus as a consequence of direct 
JNK or MST1 phosphorylation. Acetylation of FOXOs by CBP/p300 inhibits their transcriptional activity. 
Under conditions of oxidative stress this effect can be overcome by the deacetylase SIRT1. Red arrows 
indicate negative regulation, whereas green arrows indicate positive regulation. 
Fig. 1. Regulation of FOXO proteins in response to external and internal stimuli. 
In contrast, oxidative and genotoxic stress results in FOXO3 phosphorylation by c-Jun N-
terminal kinase (JNK) and by mammalian sterile 20-like kinase 1 (MST1), which forces 
translocation of FOXO transcription factors from the cytoplasm to the nucleus even in the 
presence of growth factor signaling (Sunters et al, 2006; Lehtinen et al, 2006; Essers et al, 
2004). Additional posttranslational modifications modify FOXO activity, such as acetylation 
of lysines in the forkhead domain by CBP/p300 or deacetylation by the protein deacetylase 
sirtuin-1 (SIRT1). The interaction with SIRT1 modulates the transcriptional function of 
FOXO3 resulting in the inhibition of FOXO3-induced expression of pro-apoptotic genes and 
the enhanced expression of genes involved in cell cycle regulation, DNA-repair and stress 
resistance (Brunet et al, 2004). Deacetylation of FOXO3 preferentially enhances the 
expression of genes that regulate cell cycle arrest, DNA-repair and stress resistance, which 
finally induces longevity instead of death inducing factors (Brunet et al, 2004; Furukawa-
Hibi et al, 2002). An additional mode of FOXO regulation is its proteasomal degradation, 
www.intechopen.com
 
FOXO Transcription Factors as Potential Therapeutic Targets in Neuroblastoma 
 
329 
which irreversibly shuts down FOXO activity (Hu et al, 2004). Ubiquitination by ubiquitin-
ligase Skp2 or de-ubiquitination by USP7 adds an additional level of control (van der Horst et 
al, 2006). Poly-ubiquitination depends on phosphorylation of FOXOs by PKB; Skp2 directly 
interacts with FOXO1 after PKB-specific phosphorylation at serine-253. Deacetylation by SIRT1 
and SIRT2 on the lysine residues K242, K259, K290 and K569 facilitates Skp2-mediated FOXO3 
ubiquitination and proteasomal degradation (Wang  et al, 2011). Furthermore, FOXO proteins 
have been shown to cooperate with cofactors such as Smad3/4 and the transcription factor p53 
as well as with nuclear androgen-, glucocorticoid- and retinoic acid receptors (reviewed in 
(Calnan and Brunet 2008; van der Vos and Coffer 2008)).  
4. Physiological functions of FOXOs 
FOXO transcription factors control the expression of various genes which are involved in 
cell proliferation, cell survival, DNA repair and apoptosis. Cell proliferation is controlled by 
FOXO3 via inducing the expression of cell cycle breaks such as the Cdk inhibitor (CKI) 
p27Kip1 and the retinoblastoma family member p130. Both proteins are negative regulators of 
cell cycle progression and induce cell cycle arrest in the G1 phase (Kops et al, 2002b; Dijkers 
et al, 2000b). Another FOXO3-regulated CKI p21Cip1 which is activated in response to tumor-
growth factor β (TGFβ) induces cell cycle arrest at G1. FOXO3 can directly bind to the 
transcription factors Smad3 and Smad4 and the resulting complex further binds to a 
forkhead and a smad binding element within the p21Cip1 promoter leading to increased 
p21Cip1 expression (Seoane et al, 2004). Beside activation of cell cycle inhibitors FOXO3 can 
also induce cell cycle arrest by repressing the G1 cell cycle activators cyclin D1 and D2 
(Schmidt et al, 2002; Fernandez et al, 2004). FOXO transcription factors have also been 
implicated in the control of G2-M transition and in exit from telophase. In particular FOXO3 
regulates the expression and degradation of cyclin B and of Polo-like kinase (Alvarez et al, 
2001) and the DNA damage-inducible protein 45 (Gadd45a). Under low stress conditions 
FOXO3 promotes DNA repair in a Gadd45a dependent mechanism, whereas under high 
levels of stress FOXO3 induces cell death (Furukawa-Hibi et al, 2002; Tran et al, 2002). Stress 
stimuli like hypoxia, ionizing radiation, oxidants, UV light or growth factor withdrawal 
strongly induce Gadd45a. Gadd45a is also involved in cellular mechanisms like G2-M cell 
cycle progression, genomic stability, nucleotide excision repair, apoptosis and signaling 
through MAP kinase and JNK (Lal and Gorospe 2006). Similar to PKB activity, the 
expression level, phosphorylation and subcellular localization of FOXO3 changes during the 
cell cycle, which is in part regulated by the phosphatase Cdc25A (Leisser et al, 2004). 
Importantly, FOXOs may also protect cells against reactive oxygen species (ROS) by 
inducing the two scavenger proteins superoxide dismutase (SOD2/MnSOD) and 
CAT/Catalase and may even induce therapy resistance by activating the multi-drug 
resistance gene MDR1 (Hui et al, 2008a; Kops et al, 2002a).  
FOXOs not only control proteins involved in cell cycle progression but also regulate pro- 
and anti-apoptotic genes, particularly in neurons and hematopoietic cells. Two pro-
apoptotic proteins whose expression is induced by FOXO3 are the BH3-only proteins 
PMAIP1/Noxa and BCL2L11/Bim (Dijkers et al, 2000a; Obexer et al, 2007). The Bim 
promoter contains two conserved forkhead response elements (FHRE). Binding of FOXO3 to 
these elements results in apoptotic cell death in sympathetic neurons and neuroblastoma 
cells (Gilley et al, 2003; Obexer et al, 2007). The induction of the BH3-only protein Noxa 
leads in neuroblastoma cells to apoptosis via the intrinsic death pathway (Obexer et al, 
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2007). FOXO3 also regulates the transcription of genes which are involved in the extrinsic 
death pathway, like Fas ligand (FASLG) (Brunet et al, 1999) and tumor necrosis factor-
related apoptosis inducing ligand (TRAIL). FOXO3 binds directly three FHRE within the 
regulatory region of the FASLG promoter and a novel binding site in the sequence of the 
TRAIL promoter (Modur et al, 2002). Under conditions of oxidative stress FOXO3 strongly 
induces the expression of the transcriptional repressor B-cell/lymphoma 6 (BCL6). BCL6 
represses the anti-apoptotic protein BCL2L1/Bcl-xL which contains a STAT/BCL6 binding 
site within its promoter (Tang et al, 2002). Via this indirect regulation of Bcl-xL, FOXO3 
changes the balance of pro- and anti-apoptotic proteins from survival to cell death 
induction. Interaction of FOXO factors with other transcription factors influences the 
transcriptional activity of FOXO proteins and determines the regulation of its target genes. 
β-catenin directly interacts with FOXO factors and thereby increases the expression of 
MnSOD. This leads to a shift from apoptosis regulating genes to oxidative stress detoxifying 
genes, which results in longevity (Essers et al, 2005). Another transcription factor which 
regulates FOXO3 activity is p53. Binding of p53 to FOXO3 under low stress conditions 
prevents induction of pro-apoptotic Bim and the transcriptional repressor BCL6, whereas 
expression of cyclin G2 and p27Kip1 are not affected. By modifying the target gene spectrum 
of FOXO3, the p53/FOXO3 complex induces cell cycle arrest instead of apoptosis 
(Miyaguchi et al, 2009).  
Taken together, FOXO3 is involved in various cell-type specific, cellular functions. 
Depending on its posttranslational modifications such as phosphorylation, acetylation, 
ubiquitination or interaction with other transcription factors, FOXO factors regulate even 
opposite effects, like cell cycle arrest, apoptosis induction or even induction of longevity. 
5. Regulation of FOXOs in neural stem cells and neuronal cells 
Neural stem cells are the self-renewing population that is important for proper generation of 
neurons, astrocytes and oligodendrocytes in the developing but also in the adult brain 
where they play a critical role for learning and for the brain-homeostasis during aging. They 
participate in memory, behavior, and brain injury repair.  
The insulin/IGF1/PI3K/PKB/FOXO signaling controls neural stem cell proliferation. 
Neural stem cells that overexpress PKB show an enhanced proliferation and a reduced 
capacity to differentiate (Peltier et al, 2007). In addition to maintaining the replicatory-
potential of hematopoietic stem cells (Tothova et al, 2007b) it was recently shown that 
FOXO3 knockout mice have fewer neural stem cells than wildtype mice and that neural 
stem cells isolated from FOXO3-/- mice had reduced self-renewal capacity and showed 
impaired differentiation into different neural lineages. FOXO3 knockout mice and mice with 
conditional deletion of FOXO3, FOXO4 and FOXO1 in the brain show an increased brain 
size. Furthermore their neural stem cells have enhanced rates of entry into the cell cycle 
suggesting that FOXO3 is important to maintain the relative quiescence of neural stem cells 
and prevents their premature exhaustion (Renault et al, 2009; Paik et al, 2009). One FOXO3 
target that might be critical for these neuronal abnormalities is abnormal spindle-like 
microcephaly-associated (Aspm) which is repressed by FOXO1 and FOXO3. This protein 
limits neural progenitor expansion during development and prevents early exhaustion of 
the adult neural stem cell pool (Bond et al, 2002). Adult neurogenesis relies on adult mitotic 
neural stem cells. Activation of dFOXO in Drosophila causes the elimination of these neural 
stem cells during the development via Caspase-dependent cell death (Siegrist et al, 2010). In 
www.intechopen.com
 
FOXO Transcription Factors as Potential Therapeutic Targets in Neuroblastoma 
 
331 
adult neural stem cells that lack FOXO1, FOXO3 and FOXO4 due to gene deletion, increased 
levels of reactive oxygen species (ROS) are detected. This correlates with altered expression 
of the detoxifying enzymes peroxiredoxin, glutathione peroxidase-1 and SESN3/sestrin-3. 
Since neuronal cells in particular depend on the thiol-redoxin system to defend themselves 
against ROS, regulation of these enzymes by FOXOs is critical for neuronal survival. FOXOs 
may therefore contribute to the self-renewal of neural stem cells by reducing ROS-
accumulation, which is further supported by the observation that impaired self-renewal in 
the FOXO1/3/4 triple knock out neural stem cells can be rescued by the antioxidant N-
acetyl cysteine (NAC) or the expression of SESN3 (Paik et al, 2009).  
Genome wide microarray analysis from FOXO3-/- and FOXO3+/+ neural stem cells from 
young adult mice revealed that FOXO3 regulates the neural stem cell pool by inducing 
genes that on one side promote quiescence and prevent premature differentiation  and on 
the other side are involved in oxidative stress resistance and in control of glucose 
metabolism. When comparing the FOXO3-target genes with genes necessary during the 
process of aging in human and mouse brains, Renault et al observed a correlation between 
FOXO3-regulated genes and aging-regulated genes. This suggests that FOXO3 plays a 
critical role in the regulation of nerve stem cell homeostasis and may also be critical for 
brain-aging in mammals (Renault et al, 2009). The FOXO-dependent transcriptome of neural 
stem cells has little in common with the transcriptome of other cell types such as 
hematopoietic stem cells or endothelial cells. This indicates that FOXO transcription factors 
exert cell-type specific functions (Tothova et al, 2007a; Paik et al, 2007; Paik et al, 2009).  
MicroRNAs have recently emerged as key regulators of embryonic and adult stem cells 
(Arnold et al, 2011). FOXO3 binds to a site in the first intron and thereby regulates the 
microRNA gene cluster miR-106b~25 consisting of miR-106b, miR-93 and miR-25 in primary 
cultures of neural stem/progenitor cells isolated from adult mice (Brett et al, 2011). 
Expression of this microRNA gene cluster promotes proliferation in self-renewal conditions 
and increased generation of new neurons in differentiation conditions. Therefore FOXO3 
also regulates miRNAs which are necessary for the maintenance of adult stem cells and for 
the homeostasis of the neural stem cell pool during aging (Brett et al, 2011).  
Similar to the hematopoietic system also during the development of the nerve system the 
effect of FOXO activation might completely differ between stem cells, progenitor cells and 
terminally differentiated cells. This has to be kept in mind when studying FOXO3 function 
in tumor cells that arise from different types of neuronal tumor stem cells, such as 
neuroblastoma. FOXO3 is expressed throughout the brain including hippocampal areas, 
cortex and cerebellum and may play a role during injuries that involve cerebral ischemia 
and oxidative stress (Chong et al, 2005). In primary cortical and cerebellar neurons NGF, 
NT-3 and -4, and IGF-1 mediate survival by inhibition of FOXO1 (Gan et al, 2005) and 
FOXO3 and its nuclear exclusion via the PI3K/PKB signaling pathway. Therefore during 
oxidative stress the inhibition of FOXO3 is necessary for the protective effect of trophic 
factors in neurons (Zheng et al, 2000; Zheng et al, 2002). High PKB-activity also accounts for 
neuroprotection in ischemic tolerance in hippocampal neurons (Yano et al, 2001) whereas a 
decreased PKB- and as a consequence thereof induced FOXO-activity mediates ischemia-
induced cell death. Following ischemic brain injury FOXOs induce delayed neuronal 
apoptosis via induction of FASLG and the BH3-only protein Bim in hippocampal regions. 
Neurons can be rescued from this delayed apoptosis by sodium orthovanadate which 
increases PKB-activity and therefore inhibits FOXO-dependent death signals (Fukunaga et 
al, 2005). In neonatal mice FOXO3 expression is associated with the potential to promote 
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cerebral hypoxic-ischemic injury (Pirianov et al, 2007) and the neuroprotective effects of 
estradiol during stroke are associated with inhibition of FOXO3 (Won et al, 2006). Stroke 
and reperfusion are associated with significant oxidative stress in neuronal cells and 
depending on the cell type, FOXO3 function may support survival or be detrimental. In 
neurons oxidative stress activates the tyrosine kinase c-Abl which in turn activates the 
protein kinase MST1 by phosphorylation at tyrosine-433. MST1 then phosphorylates serine-
209 in the DNA-binding domain of FOXO3, which disrupts FOXO3 interaction with 14-3-3 
proteins that are essential for the export of FOXO3 from the nucleus. This induces the 
nuclear accumulation and activation of FOXO3 even in presence of inhibitory PKB signals. 
Increased interaction of MST1 and FOXO3 activates the MST1-FOXO3 signaling pathway 
finally leading to cell death in both primary cultured neurons and rat hippocampal neurons 
(Xiao et al, 2011). Interestingly, in Drosophila the activation of the JNK/FOXO signaling 
pathway leads to neuronal resistance to oxidative stress via the expression of Jafrac1 the fly 
homologue of peroxiredoxin II. Neurons are susceptible to oxidative damage because of 
their high levels of ROS production and relatively low levels of antioxidant enzymes. 
Therefore JNK/FOXO suppresses oxidative stress-induced lethality and extends life span in 
Drosophila (Lee et al, 2009).  
6. Are FOXOs tumor suppressor proteins or do they contribute to tumor 
development? 
As FOXO transcription factors were discovered through the cloning of chromosomal 
breakpoints which were associated with cancer it was proposed that FOXOs act as tumor 
suppressors. Consistent with their putative role as tumor suppressors, overexpression of 
FOXOs in cell lines causes cell cycle arrest or cell death. However, depending on 
posttranslational modifications these transcription factors also regulate detoxification and 
stress resistance thereby protecting tumor cells from eradication during chemotherapy (Calnan 
and Brunet 2008). The dual role of FOXOs will be discussed in the following chapters. 
6.1 Role of FOXO3 in cancer cell survival and in tumor stem cells  
Although FOXOs were first described as tumor suppressor proteins, emerging data also 
suggest that FOXO transcription factors, in specific FOXO3, may have a "dark side": FOXO3 
was shown to support cancer development by protecting tumor cells against oxidative stress 
by inducing the enzyme MnSOD and PTEN-induced putative kinase-1 (Pink1) (Kops et al, 
2002a; Lee et al, 2009; Mei et al, 2009). Deletion of Pink1 sensitizes cells to growth factor 
withdrawal-induced cell death therefore demonstrating the important role of FOXO3 for 
protecting cells against growth factor depletion and oxidative stress mediated apoptosis 
(Mei et al, 2009). Furthermore FOXO3 induces via a negative feedback loop PKB survival 
signaling in chronic myelogenous leukemia cells. The acquisition of chemoresistance against 
doxorubicin correlates with activation of FOXO3 and an enhanced PI3K/PKB signaling via 
induction of PIK3CA, the PI3K catalytic subunit p110alpha (Hui et al, 2008b). In addition 
FOXO3 promotes multi-drug resistance in chronic myelogenous leukemia cells by inducing 
MDR1, a plasma membrane P-glycoprotein that functions as an efflux pump for different 
anticancer drugs. FOXO3 directly binds and activates the MDR1-promoter and increases the 
MDR1 drug efflux potential. In response to doxorubicin treatment FOXO3 induces in an 
early response cell cycle arrest and cell death but prolonged exposure promotes the 
development of cells that are drug resistant due to FOXO3-induced expression of MDR1 
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(Hui et al, 2008a). In such doxorubicin-resistant cells FOXO3 enhances PI3K/PKB signaling, 
but active PKB cannot induce the relocalization of FOXO3 from the nucleus to the cytoplasm 
suggesting that FOXO3 inactivation by PKB is hampered or that strong FOXO3 activating 
signals override inactivation by PKB. It is not clear, whether such cancer cells evolve by a 
selection process or whether a small, stem-cell like tumor cell population already exists 
which benefits from FOXO3 activation because of an already defined intrinsic “FOXO3-
stemness longevity program”.  However, in such drug-resistant cancer cells active FOXO3 
does not induce apoptosis or cell cycle arrest but leads to tumor progression and the 
development of an aggressive phenotype. Such a correlation between FOXO3 activation and 
adverse disease is not only observed in leukemic tumor cells but also in other types of 
cancer. For example in invasive ductal breast carcinoma nuclear localization of FOXO3 
correlates with lymph node positivity and predicts poor survival (Chen et al, 2010). More 
recently it was discovered that FOXO3 supports tumor cell invasion via induction of matrix 
metalloproteinase (MMP)-9 and MMP-13, both of which induce invasion and metastasis of 
solid tumors (Storz et al, 2009). FOXO3 may not only protect cells against oxidative stress 
but also prevent the detrimental effects of transitory hypoxia. FOXO3 attenuates the pro-
apoptotic response to hypoxia mediated by HIF1 in breast cancer cells by inducing the 
transcriptional cofactor CITED-2 which in turn controls HIF1 via a negative feedback loop 
(Bakker et al, 2007). These data clearly support the notion that the tumor suppressor and 
apoptosis-inducer FOXO3 may even promote cancer progression and metastasis depending 
on cell type and cellular differentiation stage. 
Recently it was shown, that FOXO3 critically regulates tumor stem cell maintenance in 
chronic myeloid leukemia (CML) which is characterized by the Bcr-Abl genetic abnormality. 
Bcr-Abl induces the PI3K/PKB signaling pathway which represses the transcriptional 
activity of FOXO3 in these cancer cells. One of the major problems of CML treatment is the 
small population of leukemia initiating cells which promote recurrence of the disease. Naka 
et al. could demonstrate that in these leukemia-initiating cell population FOXO3 localizes to 
the nucleus and promotes their maintenance and stress resistance (Naka et al, 2010). FOXO3 
seems to be the most important regulator of hematopoietic stem cells as FOXO3 is essential 
for the maintenance of the hematopoietic stem cell pool. Depletion of FOXO3 in 
hematopoietic stem cells leads to a reduced number of colony-forming cells in long-term co-
cultures of bone marrow and stromal cells, an increase in ROS levels, a deficient 
repopulating capacity in serial transplantation assays, defective maintenance of quiescence 
and a higher sensitivity to cell cycle dependent myelotoxic agents such as 5-Fluorouracil 
(Miyamoto et al, 2007). These functions of FOXO3 in normal hematopoietic stem cells are 
apparently also important for the persistence of cancer stem cells in CML.  
Neuroblastoma tumors are derived from embryonal neural stem cells in which FOXO3 may 
play an essential role in cell survival and replicative capacity similar to neural stem cells in 
the adult organism. Depending on the original cancer stem cell that gives rise to the tumor, 
FOXO3 regulation and function may differ explaining the phenomenon that some tumors 
respond well or even regress without chemotherapy, whereas others are highly resistant to 
high dose radiation and chemotherapy. Our own studies on neuroblastoma cells 
demonstrate that DNA-damaging chemotherapeutic drugs such as doxorubicin and 
etoposide which are also widely used for cancer therapy induce the accumulation of FOXO3 
in the nucleus as determined via immunofluorescence analysis in SH-EP neuroblastoma 
cells expressing a wildtype FOXO3 allele (see Figure 2). FOXO3 induces programmed cell 
death in SH-EP/FOXO3 and NB15/FOXO3 cells (Obexer et al, 2007) but may also promote 
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death resistance in neuroblastoma tumor cells after prolonged exposure of the cells to 
chemotherapeutic drugs (unpublished). In high stage neuroblastoma tumors it is frequently 
observed that almost no immune cells infiltrate the tumor tissue. The role of FOXO3 for 
immune-surveillance will be discussed in the next chapter. 
 
 
A) The localization of FOXO3 was demonstrated by immunoblot analysis of nuclear and cytoplasmic 
fractions of untreated, etoposide (20µg/ml) or doxorubicin-treated (0,25µg/ml, for 3 hours) SH-
EP/FOXO3-wt cells expressing a wildtype FOXO3 allele. After etoposide and doxorubicin treatment 
FOXO3 accumulates in the nuclear fraction. Lamin A (nuclear protein) and Tubulin (cytoplasmic 
protein) were used as purification controls. B) Immunofluorescence analyses of SH-EP/FOXO3-wt cells 
reveal that in untreated cells FOXO3 localizes to the cytoplasm whereas in etoposide and doxorubicin-
treated cells (for 3 hours) FOXO3-FITC is mainly present in the nucleus. Arrows mark nuclei with 
FOXO3-FITC staining. 
Fig. 2. Localization of FOXO3 after treatment with the chemotherapeutic agents doxorubicin 
(doxo) and etoposide (etop). 
6.2 FOXO3 represses immune function and immune surveillance 
One aspect of cancer biology that is often neglected by those who focus on signal 
transduction in cancer cells is the essential role of the immune system in eliminating 
malignant and precancerous cells. FOXO3 is also involved in this aspect of cancer 
development as it coordinates immune responses by inducing apoptosis in T-cells thereby 
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maintaining T-cell homeostasis and T-cell activity (Pandiyan et al, 2004; Dejean et al, 2009). 
Morever FOXO3 is involved in the persistence of CD4+ memory T-cells (Riou et al, 2007). 
One hallmark of FOXO3 knockout mice is that they develop a multi-inflammatory disease 
involving the intestine and various other tissues (Lin et al, 2004). This is due to the fact that 
FOXO3 affects several different players of the immune system: FOXO3 is an essential 
transcriptional regulator of FoxP3 (Harada et al, 2010) and thereby controls the 
differentiation of naive T-cells into so-called regulatory T-cells (Treg). Tregs are important in 
confining the immune reaction and in preventing autoimmune disease. In cancer, however, 
these immunosuppressive T-cells also infiltrate tumors and repress the anti-cancer activity 
of cytotoxic T-cells. A deletion of Tregs during cancer therapy, e.g. by blocking FOXO3 
could therefore boost the anti-tumor activity of the immune system. In addition it was 
shown that FOXO3 suppresses the expansion of antigen-specific effector T-cell populations 
(Wang et al, 2011) which might also hamper anti-cancer immunity. Also another branch of 
the immune system is significantly influenced by FOXO3: in stimulated dendritic cells, 
FOXO3 localizes to the nucleus and constrains the production of interleukin-6 and tumor 
necrosis factor (Dejean et al, 2009). Lack of FOXO3 in dendritic cells enhances T-cell viability 
and expansion thereby contributing to the pro-inflammatory phenotype. Importantly, in 
prostate cancer FOXO3 is highly expressed in tumor-associated dendritic cells and thereby 
induces a suppressive activity in the tumor-specific CD8+ T-cell population. Repression of 
FOXO3 in dendritic cells using siRNAs upregulated the expression of co-stimulatory 
molecules and pro-inflammatory cytokines and enhanced the immune responses (Watkins 
et al, 2011). Silencing of FOXO3 in dendritic cells can be a strategy for the enhancement of 
anti-tumor immunity and also to overcome immune tolerance. It has not been investigated 
to date, whether FOXO3 is also involved in immune suppression in neuroblastoma. 
However, these recent publications imply that FOXO3 activity might rather support the 
progression of malignancies than preventing them due to its repressive function on the 
immune system. 
6.3 FOXO3 regulates programmed cell death and death sensitivity in neuroblastoma 
cells 
6.3.1 A brief overview on cell death regulation 
Apoptosis plays a critical role in tumorigenesis and is a cellular process regulated either via 
membrane death receptors (“extrinsic pathway”) or by the balance of pro- and anti-
apoptotic proteins of the BCL2-family at the mitochondria (“intrinsic pathway”, see figure 3) 
(Coultas and Strasser 2003). In the “extrinsic” apoptosis pathway death ligands such as 
TRAIL and FASLG bind to their cognate receptors thereby inducing the formation of the so 
called “death inducing signaling complex” (DISC) which consists of the adaptor protein Fas-
associated death domain (FADD) and Procaspase-8. In this complex Caspase-8 is activated 
via autocleavage. 
The “intrinsic pathway” is triggered by developmental cues and intracellular stresses such 
as DNA-damage, growth factor withdrawal and anoikis. It is regulated at the level of 
mitochondria by the balance of pro- and anti-apoptotic BCL2-proteins, which is also termed 
BCL2-rheostat (Cory and Adams 2002). The BCL2 protein family is divided into two 
subgroups: one is the so called “multidomain” family that consists of pro-apoptotic 
members such as BAX and BAK1/Bak and pro-survival proteins e.g. BCL2, Bcl-xL, 
BCL2L2/Bcl-w and MCL1. The other subgroup is the BH3-only family, a large group of 
apoptosis-inducers such as Noxa, BBC3/Puma, BID and Bim. The BH3-only proteins 
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interact with the anti-apoptotic BCL2-proteins thereby antagonizing their pro-survival 
function (Coultas and Strasser 2003; Shibue and Taniguchi 2006). Two models have been 
proposed for apoptosis induction by BH3-only proteins: In the “direct activator/de-
repressor model” (Kim et al, 2006) strong BH3-only proteins such as Bim, Puma and 
truncated BID act as direct activators of BAX, whereas in the “displacement model” (Labi et 
al, 2006; Willis et al, 2007) these three proteins are potent neutralizers of all five BCL2-like 
pro-survival proteins. Weak BH3-only proteins such as Noxa act as sensitizers by 
inactivating specific pro-survival BCL2-proteins. Oligomerization of BAX or Bak in the 
mitochondrial outer membrane causes release of Cytochrome-c from mitochondria. 
Cytochrome-c binds to APAF1 that recruits Procaspase-9 and activates the so-called 
“apoptosome”. Once activated Caspase-8 and Caspase-9 cleave the downstream effector 
Caspases-3 and -7 which provoke cellular destruction, nuclear DNA fragmentation and 
apoptotic cell death. In some cells, the two pathways intersect since Caspase-8 can process 
the BCL2-family member BID into its active truncated form (Scaffidi et al, 1998) and thereby 
activate mitochondrial death signaling. 
The activity of Caspases is counteracted by members of the inhibitor of apoptosis protein 
(IAP) family. In contrast to other IAPs (XIAP, c-IAP1, c-IAP2, NAIP) BIRC5/Survivin 
contains only a single baculovirus IAP repeat (BIR) and lacks the RING finger domain. Its 
apoptosis-protecting function therefore is still under debate: Survivin was shown to inhibit 
effector Caspases via its single BIR domain, but also to act upstream at the level of 
mitochondria (Shankar et al, 2001; Liu et al, 2004). Survivin is frequently expressed in 
various malignancies, among them neuroblastoma and leukemia (Adida et al, 1998; Adida 
et al, 2000; Granziero et al, 2001; Islam et al, 2000). In neuroblastoma the expression of 
Survivin has been reported to correlate with a reduced apoptotic index in vivo, with a 
shortened overall survival rate, an unfavorable prognosis and an increased relapse rate. We 
have shown that FOXO3 is an upstream regulator of Survivin in neuroblastoma and that 























Fig. 3. Schematic presentation of “extrinsic” and “intrinsic” apoptosis signaling in 
mammalian cells.  
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6.3.2 FOXO3 in neuroblastoma cells 
In neuroblastoma tumors the PI3K/PKB signaling pathway is frequently hyperactivated 
which leads to proliferation and therapy resistance of the tumor cells. PTEN mutations are 
rare (below 10%) in neuroblastoma but altered expression of PICT-1, a PTEN-stabilizing 
protein (Okahara et al, 2006) and aberrant neurotrophic factor signaling may be responsible 
for the hyperactivation of this signaling pathway. Hyperactivation of PKB was identified as 
a novel prognostic indicator for adverse clinical outcome and overall survival in 
neuroblastoma as it correlates with NMYC-amplification, 1p36 deletion, advanced disease 
stage, age at diagnosis and unfavorable histology (Opel et al, 2007). Several studies indicate 
that BDNF, by binding to its cognate receptor TrkB (BDNF and TrkB being markers for a 
poor 5-year survival outcome) increases neuroblastoma tumor cell survival (Feng et al, 2001; 
Matsumoto et al, 1995; Nakagawara et al, 1993), cell invasion (Matsumoto et al, 1995) and 
protects neuroblastoma cells from chemotherapy (Middlemas et al, 1999; Scala et al, 1996). 
BDNF promotes neurite extension (Nakagawara et al, 1993) and survival of sensory neurons 
(Acheson et al, 1995) under normal conditions. It was shown that the ability of BDNF to 
rescue neuroblastoma cells from chemotherapy-induced cell death was abrogated by the 
treatment with the tyrosine kinase inhibitor K252a or the PI3K-inhibitor Ly294002, 
indicating that both TrkB and PI3K activities are required for survival (Jaboin et al, 2002). In 
this context, the transcription factors FOXO1, FOXO3 and FOXO4 have been reported to be 
regulated downstream of Trk receptor signaling (Mai et al, 2002). They can induce apoptosis 
of cerebellar granule neurons (Brunet et al, 1999). In cortical neurons NGF, BDNF, NT-3 and 
NT-4 cause inactivation of FOXO3 by phosphorylation through PKB and SGK leading to 
neurotrophin-mediated cell survival of rat neurons. In concordance the PI3K inhibitor 
Ly294002 caused decreased phosphorylation of FOXO3 and induced cell death in these rat 
cells (Zheng et al, 2002). In SH-SY5Y neuroblastoma cells IGF-I signaling is associated with 
PKB-mediated phosphorylation of FOXO3 and its translocation into the cytoplasm. During 
growth factor withdrawal-induced apoptosis FOXO3 is imported into the nucleus in these 
cells (Schwab et al, 2005). Both, TrkB and BDNF may contribute to the chemoresistance of 
poor prognosis tumors and the suppression of PI3K activity or activation of further 
downstream targets of this pathway, such as FOXO3, could therefore significantly increase 
the effects of therapeutic agents on neuroblastoma tumors.  
To analyze the connection between deregulated PI3K/PKB survival signaling and impaired 
apoptotic cell death in neuroblastoma, we determined the protein levels of PKB, FOXO3, 
phospho-PKB (serine-473) and phospho-FOXO3 (threonine-32) by immunoblot in different 
neuroblastoma cell lines and found that PKB and FOXO3 were phosphorylated, suggesting 
the inactivation of FOXO3. To study the function of FOXO3 we infected SH-EP and STA-
NB15 neuroblastoma cells (Narath et al, 2007) with retroviruses coding for a 4OH-tamoxifen 
(4OHT)-regulated FOXO3(A3)ERtm transgene. In the untreated condition this fusion protein 
is expressed in the cytoplasm. Upon addition of 4OHT it translocates into the nucleus and 
regulates FOXO3 target genes. Activation of FOXO3 in SH-EP/FOXO3 and NB15/FOXO3 
cells promoted loss of mitochondrial activity, Cytochrome-c-release and Caspase-dependent 
apoptosis. FOXO3 induced TRAIL and the BH3-only proteins Noxa and Bim as measured by 
real time RT-PCR and immunoblot implicating both, extrinsic and intrinsic death pathways. 
However, expression of dominant negative FADD, which blocks the formation of the DISC 
and activation of Caspase-8, did not inhibit FOXO3-induced cell death, whereas transgenic 
expression of BCL2 protected against apoptosis. This excluded the death receptor pathway 
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and suggested that cell death decision is regulated by BCL2-rheostat. Importantly, shRNA-
knockdown of the pro-apoptotic BH3-only proteins Noxa or Bim decreased apoptosis, 
indicating that Noxa and Bim cooperate to mediate FOXO3-induced cell death. In this work 
we described for the first time that Noxa and Bim establish a connection between FOXO3 
and mitochondria and that both BH3-only proteins are critically involved in FOXO3-
induced apoptosis in neuroblastoma (Obexer et al, 2007). In a second paper we 
demonstrated for the first time that repression of the apoptosis inhibitor protein 
BIRC5/Survivin by FOXO3 sensitizes neuroblastoma cells to DNA-damage- and FOXO3-
mediated apoptosis. The survivin gene is located at 17q25 an area that is frequently altered 
in neuroblastoma. Gain of chromosome 17q or the distal translocation of 17q is of prognostic 
relevance and correlates with aggressive tumors (Islam et al, 2000). Since activated PKB 
protects neuroblastoma cells from chemotherapy-induced apoptosis and both, active PKB 
and Survivin are predictive for an adverse clinical outcome we analyzed a possible 
connection between PKB and Survivin. We found that inhibition of the PI3K/PKB signaling 
pathway by the PI3K-inhibitor Ly294002 induces nuclear accumulation of FOXO3 and 
subsequently represses the pro-survival protein Survivin. Conditional FOXO3 activation 
repressed Survivin transcription and protein expression. Since the repression of Survivin by 
FOXO3 can be blocked by cycloheximide we found that in neuroblastoma FOXO3 rather 
indirectly downregulates the survivin promoter activity. Transgenic Survivin expression 
exerted a significant anti-apoptotic effect and prevented the accumulation of Bim and BAX 
at the mitochondria, the loss of mitochondrial membrane potential as well as the release of 
Cytochrome-c during FOXO3-activation and significantly delayed apoptosis. In 
concordance, Survivin knockdown by retroviral shRNA-technology accelerated FOXO3-
induced apoptosis. In this paper we further demonstrated that low-level activation of 
FOXO3 sensitized neuroblastoma cells to the DNA-damaging agents doxorubicin and 
etoposide, whereas the overexpression of Survivin diminished FOXO3-sensitization to these 
drugs. These results suggest that repression of Survivin by FOXO3 facilitates FOXO3-
induced apoptosis and sensitizes neuroblastoma cells to apoptosis induced by DNA-
damaging agents, which supports the central role of PI3K-PKB-FOXO3 signaling in drug 
resistance of human neuroblastoma (Obexer et al, 2009).  
As FOXO3 induction seems to be beneficial for the treatment in neuroblastoma, we searched 
for natural compounds that might activate FOXO3. The phytochemical indol-3-carbinol (I3C) 
which derives from cruciferous vegetables, has been shown to induce cell cycle arrest and 
apoptosis by targeting BCL2 and the cyclin-dependent kinase inhibitor p27Kip1 in colon cancer 
cells (Aggarwal and Ichikawa 2005). In neuroblastoma cells I3C induces cell death in various 
cell lines, such as SH-EP, STA-NB1 and STA-NB15. I3C-mediated apoptosis can be blocked via 
the pan-Caspase-inhibitor zVAD and also via the Caspase-9 inhibitor LEHD demonstrating 
that I3C induces Caspases-dependent cell death (figure 4A). In SH-EP cells treatment with I3C 
induced the expression of the BH3-only proteins Noxa and Bim already 4 hours after I3C-
treatment and reduced the expression of Survivin after 8 hours (figure 4C). As all three 
proteins are transcriptional targets of FOXO3 we hypothesized that I3C might induce the 
translocation and thereby activation of endogenous FOXO3 in neuroblastoma cells. To answer 
this question we generated SH-EP cells that express an enhanced cyan fluorescent protein 
(ECFP)-FOXO3 fusion protein which localizes to the cytoplasm in untreated cells. Already 30 
minutes after I3C treatment FOXO3 shuttles into the nucleus and after 3 hours almost all cells 
show nuclear FOXO3 demonstrating that I3C leads to FOXO3-activation (Figure 4B).  
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A) SH-EP cells were treated for 24 and 48 hours with I3C (100µM) alone or in combination with the 
Caspase-9 inhibitor LEHD, or the pan-Caspase-inhibitor zVAD. Apoptosis was determined by PI-FACS 
analysis. B) SH-EP cells were retrovirally infected with a plasmid coding for ECFP-FOXO3. Treatment 
of these SH-EP/ECFP-FOXO3 cells for 30, 60 and 180 minutes with 100µM I3C induced translocation of 
FOXO3 from the cytoplasm to the nucleus as analyzed by live cell fluorescence imaging in an 
Axiovert200M microscope (Zeiss). C) SH-EP cells were treated for 4, 8, 16 and 24 hours with 100µM I3C 
and the expression of Noxa, Bim and Survivin was determined by immunoblot. GAPDH was used as 
loading control. D) SH-EP cells were retrovirally infected with plasmids coding for BCL2, BclxL, CrmA 
and MCL1. These transgenic cell lines were treated for 24, 48 and 72 hours with 100µM I3C and 
apoptosis was analyzed by PI-FACS-analysis. 
Fig. 4. I3C activates FOXO3 and induces apoptosis in neuroblastoma cells.  
Similar to FOXO3-induced apoptosis also I3C-mediated cell death is inhibited by the 
prosurvival proteins BCL-2 and BclxL implicating that BCL2-rheostat is essential for the 
control of I3C-induced apoptosis (Obexer et al, 2007). In addition, ectopic expression of 
CrmA, a Caspase-8 inhibitor of the Cowpox virus, reduced I3C-induced apoptosis 
suggesting that active Caspase-3 might cleave Caspase-8 and thereby initiate a death-
inducing feedback loop. This is also consistent with FOXO3-induced cell death in 
neuroblastoma cells. Ectopic expression of the pro-survival protein MCL1 had no effect on 
I3C-mediated apoptosis (figure 4D). The combined results implicate that I3C induces 
apoptosis at least in part via induction of FOXO3 which in turn activates the BH3-only 
proteins Bim and Noxa and represses the anti-apoptotic protein Survivin. As inactivation of 
FOXO3 in malignant neuroblastoma cells critically contributes to apoptosis resistance, 
strategies to activate FOXO3 in neuroblastoma despite aberrant PKB-signaling, for example 
by I3C and thereby to restore the function of a deregulated PKB-FOXO3 pathway, may 
improve the therapy of this malignant disease. 
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7. Conclusions: FOXO3 – a double-edged sword in therapeutic intervention 
FOXO transcription factors were originally identified as tumor suppressor proteins that, when 
activated or overexpressed in tumor cells, trigger the expression of apoptosis-inducers of the 
BCL2-family or of the death ligand family. FOXOs integrate a plethora of different signals and 
translate them into complex, cell-type dependent gene expression patterns. Their 
transcriptional targets regulate cell cycle arrest and cell death, but may also promote stress 
resistance and longevity. Therefore the effects of FOXO3 activation might completely differ 
between different tumor types, but also between differentiation stages of cancer cells within 
one tumor. This is in particular of importance in human neuroblastoma, which frequently 
contain tumor cells of various differentiation states. Although in experimental systems with 
relatively homogenous cell populations FOXO3 is an efficient killer of neuroblastoma cells, the 
in vivo situation might completely differ and active FOXO3 may even support the survival of 
specific subpopulations of cancer-initiating cells during chemotherapy. The immune-
suppressive function of FOXO3 adds an additional level of complexity in the role of FOXOs 
during cancer development and cancer surveillance. In particular in high-stage 
neuroblastoma, where immune infiltrations are almost absent, the activation of FOXO3 in 
immune cells, possibly as an unwanted side-effect of chemotherapy, may shut down tumor-
specific cytotoxic immune responses. Therefore it has to be carefully investigated for which 
specific subtype of cancer FOXO3 is an attractive target and whether the inhibition of FOXO3 
in immune cells may boost anti-cancer immune responses. So this double-edged sword has to 
be manipulated and handled with care otherwise it will cause detrimental damage.  
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